Seguridad y tolerabilidad de etravirina
Safety and tolerability of etravirine
Joaquín Portilla
Unidad de Enfermedades Infecciosas, Hospital General Universitario de Alicante, Alicante, España
Leído
2783
Vecesse ha leído el artículo
773
Total PDF
2010
Total HTML
Compartir estadísticas
array:23 [ "pii" => "S0213005X0973215X" "issn" => "0213005X" "doi" => "10.1016/S0213-005X(09)73215-X" "estado" => "S300" "fechaPublicacion" => "2009-12-01" "aid" => "73215" "copyright" => "Elsevier España S.L.. Todos los derechos reservados" "copyrightAnyo" => "2009" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Enferm Infecc Microbiol Clin. 2009;27 Supl 2:21-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1846 "formatos" => array:3 [ "EPUB" => 8 "HTML" => 1404 "PDF" => 434 ] ] "itemSiguiente" => array:18 [ "pii" => "S0213005X09732161" "issn" => "0213005X" "doi" => "10.1016/S0213-005X(09)73216-1" "estado" => "S300" "fechaPublicacion" => "2009-12-01" "aid" => "73216" "copyright" => "Elsevier España S.L." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Enferm Infecc Microbiol Clin. 2009;27 Supl 2:27-31" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2164 "formatos" => array:3 [ "EPUB" => 8 "HTML" => 1499 "PDF" => 657 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Interacciones medicamentosas de etravirina" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "27" "paginaFinal" => "31" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Etravirine drug interactions" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Vicente Estrada Pérez, Clara Sánchez-Parra, Sergio Serrano Villar" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Vicente Estrada" "apellidos" => "Pérez" ] 1 => array:2 [ "nombre" => "Clara" "apellidos" => "Sánchez-Parra" ] 2 => array:2 [ "nombre" => "Sergio Serrano" "apellidos" => "Villar" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X09732161?idApp=UINPBA00004N" "url" => "/0213005X/00000027000000S2/v1_201305090145/S0213005X09732161/v1_201305090145/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0213005X09732148" "issn" => "0213005X" "doi" => "10.1016/S0213-005X(09)73214-8" "estado" => "S300" "fechaPublicacion" => "2009-12-01" "aid" => "73214" "copyright" => "Elsevier España S.L." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Enferm Infecc Microbiol Clin. 2009;27 Supl 2:12-20" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1995 "formatos" => array:3 [ "EPUB" => 10 "HTML" => 1502 "PDF" => 483 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Etravirina en primeras líneas de tratamiento" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "12" "paginaFinal" => "20" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Etravirine in first-line therapy" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Piedad Arazo Garcés, Esther Valero Tena" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Piedad Arazo" "apellidos" => "Garcés" ] 1 => array:2 [ "nombre" => "Esther Valero" "apellidos" => "Tena" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X09732148?idApp=UINPBA00004N" "url" => "/0213005X/00000027000000S2/v1_201305090145/S0213005X09732148/v1_201305090145/es/main.assets" ] "es" => array:12 [ "idiomaDefecto" => true "titulo" => "Seguridad y tolerabilidad de etravirina" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "21" "paginaFinal" => "26" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Joaquín Portilla" "autores" => array:1 [ 0 => array:3 [ "nombre" => "Joaquín" "apellidos" => "Portilla" "email" => array:1 [ 0 => "portilla_joa@gva.es" ] ] ] "afiliaciones" => array:1 [ 0 => array:1 [ "entidad" => "Unidad de Enfermedades Infecciosas, Hospital General Universitario de Alicante, Alicante, España" ] ] ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Safety and tolerability of etravirine" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec137942" "palabras" => array:5 [ 0 => "Etravirina" 1 => "Inhibidores no nucleósidos de la transcriptasa inversa" 2 => "Infección por VIH" 3 => "Efectos adversos" 4 => "Exantema" ] ] ] "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Key words" "identificador" => "xpalclavsec137941" "palabras" => array:5 [ 0 => "Etravirine" 1 => "Non-nucleoside reverse transcriptase inhibitors" 2 => "HIV infection" 3 => "Adverse effects" 4 => "Rash" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<p class="elsevierStyleSimplePara elsevierViewall">Etravirina (ETR) es el primer representante de una nueva generación de inhibidores de la transcriptasa inversa no análogos de nucleósidos (ITINAN), y está indicado en el tratamiento de pacientes con infección por VIH en situación de fracaso virológico. La dosis recomendada es de 200 mg (2 comprimidos) cada 12 h, después de una comida. La tolerabilidad a ETR es buena, los comprimidos son fácilmente dispersables en agua y ello puede mejorar la deglución de los comprimidos en algunos pacientes. ETR tiene una vida media en plasma de 30-40 h, por ello es un fármaco candidato a pautas de 1 vez al día. El exantema cutáneo es el efecto adverso más frecuente en pacientes que reciben ETR (19%), suele ser leve (grados 1 o 2) y no obliga a suspender el fármaco. Los estudios DUET-1 y 2, que compararon ETR frente a placebo, ambos grupos con darunavir potenciado y terapia optimizada, no demostraron una mayor incidencia de toxicidad hepática, síntomas neuropsiquiátricos, trastornos gastrointestinales o dislipemia aterógena en los pacientes que recibieron ETR. El perfil de seguridad de ETR sugiere que podría utilizarse como fármaco de sustitución en pacientes con toxicidad inducida por ITINAN de primera generación u otros fármacos antirretrovirales.</p>" ] "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<p class="elsevierStyleSimplePara elsevierViewall">Etravirine (ETR) is the first representative of a new generation of non-nucleoside reverse transcriptase inhibitors (NNRTI) and is indicated in patients with HIV infection and virological failure. The recommended dose is 200 mg (two tablets) every 12 hours after a meal. ETR has good tolerability and the tablets can be dissolved in water, which can aid swallowing in some patients. This drug has a plasma half-life of 30-40 hours and consequently is a candidate for once-daily regimens. The most frequent adverse effect is rash (affecting 19% of patients), which is usually mild (grades 1 or 2) and does not lead to drug withdrawal. The DUET 1 and 2 studies, which compared ETR versus placebo, with both groups receiving boosted darunavir and an optimized background regimen, did not demonstrate a higher incidence of liver toxicity, neuropsychiatric symptoms, gastrointestinal disturbances or atherogenic dyslipidemia in patients receiving ETR. The safety profile of ETR suggests that it could be used as a substitute drug in patients with toxicity induced by first-generation NNRTIs or other antiretroviral drugs.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "Bibliografía" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:34 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "R. Pauwels" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.coph.2004.07.005" "Revista" => array:6 [ "tituloSerie" => "Curr Opin Pharmacol" "fecha" => "2004" "volumen" => "4" "paginaInicial" => "437" "paginaFinal" => "446" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15351347" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Delavirdine. A review of its use in HIV infection" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "L.J. Scott" 1 => "C.M. Perry" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Drugs" "fecha" => "2000" "volumen" => "60" "paginaInicial" => "1411" "paginaFinal" => "1444" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11152019" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Rivero" 1 => "J.A. Mira" 2 => "J.A. Pineda" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/jac/dkl524" "Revista" => array:6 [ "tituloSerie" => "J Antimicrob Chemother" "fecha" => "2007" "volumen" => "59" "paginaInicial" => "342" "paginaFinal" => "346" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17255142" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "Panel de Expertos de Gesida, Plan Nacional Sobre El Sida" "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eimc.2008.11.002" "Revista" => array:6 [ "tituloSerie" => "Enferm Infecc Microbiol Clin" "fecha" => "2009" "volumen" => "27" "paginaInicial" => "222" "paginaFinal" => "235" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19246124" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Randomized, controlled study of the effects of short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.S. Montaner" 1 => "P. Cahn" 2 => "C. Zala" 3 => "L.I. Cassetti" 4 => "M. Losso" 5 => "D.B. Hall" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Acquir Immene Defic Syndr" "fecha" => "2003" "volumen" => "33" "paginaInicial" => "41" "paginaFinal" => "46" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H. Knobel" 1 => "J.M. Miró" 2 => "B. Mahillo" 3 => "P. Domingo" 4 => "A. Rivero" 5 => "E. Ribera" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Acquir Immune Defic Syndr" "fecha" => "2004" "volumen" => "37" "paginaInicial" => "1276" "paginaFinal" => "1281" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15385735" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "F. Van Leth" 1 => "P. Phanuphak" 2 => "K. Ruxrungtham" 3 => "E. Baraldi" 4 => "S. Miller" 5 => "B. Gazzard" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Lancet" "fecha" => "2004" "volumen" => "363" "paginaInicial" => "1253" "paginaFinal" => "1263" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D.B. Clifford" 1 => "S. Evans" 2 => "Y. Yang" 3 => "E.P. Acosta" 4 => "K. Goodkin" 5 => "K. Tashima" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Ann Intern Med" "fecha" => "2005" "volumen" => "143" "paginaInicial" => "714" "paginaFinal" => "721" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16287792" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Blanch" 1 => "E. Martínez" 2 => "A. Rousaud" 3 => "J.L. Blanco" 4 => "M.A. García-Viejo" 5 => "J.M. Peri" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Acquir Immune Defic Syndr" "fecha" => "2001" "volumen" => "27" "paginaInicial" => "336" "paginaFinal" => "343" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11468421" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Longterm neuropsychiatric disorders on efavirenz-based approaches: quality of life, psycologic issues and adherence" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C.R. Fumaz" 1 => "J.A. Muñoz-Moreno" 2 => "J. Moltó" 3 => "E. Negredo" 4 => "M.J. Ferrer" 5 => "G. Sirera" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Acquir Immune Defic Syndr" "fecha" => "2005" "volumen" => "38" "paginaInicial" => "560" "paginaFinal" => "565" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15793366" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "V. Journot" 1 => "G. Chene" 2 => "N. De Castro" 3 => "C. Rancinan" 4 => "J.P. Cassuto" 5 => "C. Allard" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/504323" "Revista" => array:6 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2006" "volumen" => "42" "paginaInicial" => "1790" "paginaFinal" => "1799" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16705588" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "E. Arroyo" 1 => "B. Valenzuela" 2 => "J. Portilla" 3 => "E. Climent-Grana" 4 => "J.J. Pérez-Ruixo" 5 => "E. Merino" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00228-007-0299-z" "Revista" => array:6 [ "tituloSerie" => "Eur J Clin Pharmacol" "fecha" => "2007" "volumen" => "63" "paginaInicial" => "669" "paginaFinal" => "675" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17473920" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naïve patients infected with HIV-1" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Van Leth" 1 => "P. Phanuphak" 2 => "E. Stroes" 3 => "B. Gazzard" 4 => "P. Cahn" 5 => "RaffiF F." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pmed.0010019" "Revista" => array:5 [ "tituloSerie" => "PLos Med" "fecha" => "2004" "volumen" => "1" "paginaInicial" => "e19" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15526045" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.H. Haubrich" 1 => "S.A. Riddler" 2 => "A.G. DiRienzo" 3 => "L. Komarow" 4 => "W.G. Powderly" 5 => "K. Klingman" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/QAD.0b013e32832b4377" "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "2009" "volumen" => "23" "paginaInicial" => "1109" "paginaFinal" => "1118" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19417580" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.R. Arribas" 1 => "A.L. Pozniak" 2 => "J.E. Gallant" 3 => "E. DeJesus" 4 => "B. Gazzard" 5 => "R.E. Campo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/QAI.0b013e31815acab8" "Revista" => array:6 [ "tituloSerie" => "J Acquir Immune Defic Syndr" "fecha" => "2008" "volumen" => "47" "paginaInicial" => "74" "paginaFinal" => "78" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17971715" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. DeJesus" 1 => "G. Herrera" 2 => "E. Teofilo" 3 => "J. Gerstoft" 4 => "C.B. Buendía" 5 => "J.D. Brand" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2004" "volumen" => "39" "paginaInicial" => "1038" "paginaFinal" => "1046" ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Sustiva(r), ficha técnica [consultado 15-7-2009] Disponible en: <a class="elsevierStyleInterRef" href="http://www.emea.europa.eu/humandocs/Humans/EPAR/sustiva/sustiva.htm">http://www.emea.europa.eu/humandocs/Humans/EPAR/sustiva/sustiva.htm</a>" ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Viramune(r), ficha técnica [consultado 15-7-2009] Disponible en: <a class="elsevierStyleInterRef" href="http://www.emea.europa.eu/humandocs/Humans/EPAR/viramune/viramune.htm">http://www.emea.europa.eu/humandocs/Humans/EPAR/viramune/viramune.htm</a>" ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etravirine" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "E.D. Deeks" 1 => "G.M. Keating" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Drugs" "fecha" => "2008" "volumen" => "68" "paginaInicial" => "2357" "paginaFinal" => "2372" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18973398" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etravirine, a next-generation nonnucleoside reversetranscriptase inhibitor" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "L.B. Johnson" 1 => "L.D. Saravolatz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/597469" "Revista" => array:6 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2009" "volumen" => "48" "paginaInicial" => "1123" "paginaFinal" => "1128" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19275497" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "L. Garvey" 1 => "A. Winston" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1517/13543780903055056" "Revista" => array:6 [ "tituloSerie" => "Expert Opin Investig Drugs" "fecha" => "2009" "volumen" => "18" "paginaInicial" => "1035" "paginaFinal" => "1041" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19548857" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib22" "etiqueta" => "22." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Intelence(r), ficha técnica [consultado 15-7-2009] Disponible en: <a class="elsevierStyleInterRef" href="http://www.emea.europa.eu/humandocs/Humans/EPAR/intelence/intelence.htm">http://www.emea.europa.eu/humandocs/Humans/EPAR/intelence/intelence.htm</a>" ] ] ] 22 => array:3 [ "identificador" => "bib23" "etiqueta" => "23." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etravirine has no effect on qt and corrected QT interval in HIV-negative volunteers" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Peeters" 1 => "K. Janssen" 2 => "T.N. Kakuda" 3 => "M. Schöller-Gyüre" 4 => "R. Lachaert" 5 => "R.M. Hoetelmans" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Ann Pharmacoth" "fecha" => "2008" "volumen" => "42" "paginaInicial" => "757" "paginaFinal" => "765" ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib24" "etiqueta" => "24." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacokinetics of once-daily etravirine without or with once-daily darunavir/ritonavir in antirretroviral- naive HIV-1 infected patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Lalezari" 1 => "E. DeJesus" 2 => "O. Osiyemi" 3 => "P. Ruane" 4 => "Z. Haigney" 5 => "R. Ryan" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "Ninth International Congress on Drug Therapy in HIV Infection (HIV9)" "conferencia" => "Glasgow. November 9-13" "serieFecha" => "2008" ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib25" "etiqueta" => "25." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.V. Madruga" 1 => "D. Berger" 2 => "M. McMurchie" 3 => "F. Suter" 4 => "D. Banhegyi" 5 => "K. Ruxrungtham" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(07)61049-6" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2007" "volumen" => "370" "paginaInicial" => "49" "paginaFinal" => "58" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17617272" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib26" "etiqueta" => "26." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Lazzarin" 1 => "T. Campbell" 2 => "B. Clotet" 3 => "M. Johnson" 4 => "C. Katlama" 5 => "A. Moll" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(07)61048-4" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2007" "volumen" => "370" "paginaInicial" => "39" "paginaFinal" => "48" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17617271" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib27" "etiqueta" => "27." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "DUET- 1: week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus placebo in 612 treatmentexperienced HIV-1 infected patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Haubrich" 1 => "P. Cahn" 2 => "B. Grinsztejn" 3 => "J. Lalezari" 4 => "J. Valdez Madruga" 5 => "A. Mills" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "15th Conference on Retroviruses and Opportunistic Infections" "conferencia" => "Boston" "serieFecha" => "2008" ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib28" "etiqueta" => "28." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "DUET-2: week-48 results of a phase III randomized double-blind trial to evaluate the effi- cacy and safety of etravirine (ETR; TMC125) versus placebo in 591 treatment-experienced HIV-1 infected patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Johnson" 1 => "T. Campbell" 2 => "B. Clotet" 3 => "C. Katlama" 4 => "A. Lazzarin" 5 => "W. Towner" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "15th Conference on Retroviruses and Opportunistic Infections" "conferencia" => "Boston" "serieFecha" => "2008" ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib29" "etiqueta" => "29." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pooled 24-week results of DUET-1 and -2; TMC125 (etravirine) safety and tolerability in treatment-experienced HIV-1-infected patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Di Perri" 1 => "P.M. Girard" 2 => "N. Clumeck" 3 => "M. Peeters" 4 => "M. Janssens" 5 => "G. De Smedt" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "11 th European AIDS Conference" "conferencia" => "Madrid" "serieFecha" => "2007" ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib30" "etiqueta" => "30." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Campbell T, Mills A, Morlat P, Schechter M, De Smedt G, Peeters M, et al. TMC125 safety and tolerability in treatment experienced patientes hepatitis B or C coinfected patients in DUET-1 and DUET-2. HEP DART: Frontiers in Drug Development for Antiretroviral Therapies. Lahaina (HI), USA. 2007, Dec 9-13. Abstract 96." ] ] ] 30 => array:3 [ "identificador" => "bib31" "etiqueta" => "31." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of TMC125, a next generation NNRTI, on clinical outcomes (AIDS-defining illnesses and deaths): 24-week findings from a planned pooled analysis of the DUET studies" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J. Gatell" 1 => "G. Beatty" 2 => "M. Johnson" 3 => "S. Martin" 4 => "M. Peeters" 5 => "B. Woodfall" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "11th European AIDS Conference" "conferencia" => "Madrid" "serieFecha" => "2007" ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib32" "etiqueta" => "32." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Health-related quality of life (HRQL) as measured by the Functional Assesment of HIV Infection (FAHI) questionnaire in treatment-experienced HIV-1 infected patients: 24-week results from the pooled DUET trials" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "K. Peeters" 1 => "M. Viala" 2 => "H. Gilet" 3 => "B. Woodfall" 4 => "D. Dubois" 5 => "D. Cella" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "11 th European AIDS Conference" "conferencia" => "Madrid" "serieFecha" => "2007" ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib33" "etiqueta" => "33." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Stability of antiretroviral regimens in patients with viral suppression" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.K. Lodwick" 1 => "C.J. Smith" 2 => "M. Youle" 3 => "F.C. Lampe" 4 => "M. Tyrer" 5 => "S. Bhagani" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/QAD.0b013e3282fec415" "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "2008" "volumen" => "22" "paginaInicial" => "1039" "paginaFinal" => "1046" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18520347" "web" => "Medline" ] ] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib34" "etiqueta" => "34." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antiretroviral therapy. Optimal sequencing of therapy to avoid resistance" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J.L. Martínez-Cajas" 1 => "M.A. Wainberg" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Drugs" "fecha" => "2008" "volumen" => "68" "paginaInicial" => "43" "paginaFinal" => "72" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18081372" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "es" "url" => "/0213005X/00000027000000S2/v1_201305090145/S0213005X0973215X/v1_201305090145/es/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/0213005X/00000027000000S2/v1_201305090145/S0213005X0973215X/v1_201305090145/es/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X0973215X?idApp=UINPBA00004N" ]
| año/Mes | Html | Total | |
|---|---|---|---|
| 2024 Noviembre | 3 | 0 | 3 |
| 2024 Octubre | 10 | 3 | 13 |
| 2024 Septiembre | 23 | 16 | 39 |
| 2024 Agosto | 9 | 7 | 16 |
| 2024 Julio | 7 | 3 | 10 |
| 2024 Junio | 8 | 3 | 11 |
| 2024 Mayo | 11 | 2 | 13 |
| 2024 Abril | 13 | 5 | 18 |
| 2024 Marzo | 14 | 3 | 17 |
| 2024 Febrero | 5 | 1 | 6 |
| 2024 Enero | 6 | 1 | 7 |
| 2023 Diciembre | 13 | 3 | 16 |
| 2023 Noviembre | 4 | 1 | 5 |
| 2023 Octubre | 8 | 4 | 12 |
| 2023 Septiembre | 9 | 2 | 11 |
| 2023 Agosto | 4 | 1 | 5 |
| 2023 Julio | 4 | 2 | 6 |
| 2023 Junio | 23 | 1 | 24 |
| 2023 Mayo | 21 | 3 | 24 |
| 2023 Abril | 22 | 1 | 23 |
| 2023 Marzo | 27 | 1 | 28 |
| 2023 Febrero | 5 | 6 | 11 |
| 2023 Enero | 4 | 3 | 7 |
| 2022 Diciembre | 8 | 3 | 11 |
| 2022 Noviembre | 10 | 5 | 15 |
| 2022 Octubre | 7 | 9 | 16 |
| 2022 Septiembre | 9 | 10 | 19 |
| 2022 Agosto | 8 | 16 | 24 |
| 2022 Julio | 7 | 7 | 14 |
| 2022 Junio | 6 | 5 | 11 |
| 2022 Mayo | 12 | 8 | 20 |
| 2022 Abril | 7 | 14 | 21 |
| 2022 Marzo | 7 | 13 | 20 |
| 2022 Febrero | 8 | 3 | 11 |
| 2022 Enero | 16 | 7 | 23 |
| 2021 Diciembre | 9 | 10 | 19 |
| 2021 Noviembre | 7 | 9 | 16 |
| 2021 Octubre | 9 | 6 | 15 |
| 2021 Septiembre | 6 | 9 | 15 |
| 2021 Agosto | 6 | 9 | 15 |
| 2021 Julio | 7 | 3 | 10 |
| 2021 Junio | 11 | 7 | 18 |
| 2021 Mayo | 8 | 9 | 17 |
| 2021 Abril | 11 | 18 | 29 |
| 2021 Marzo | 60 | 10 | 70 |
| 2021 Febrero | 8 | 4 | 12 |
| 2021 Enero | 13 | 15 | 28 |
| 2020 Diciembre | 6 | 3 | 9 |
| 2020 Noviembre | 10 | 5 | 15 |
| 2020 Octubre | 8 | 5 | 13 |
| 2020 Septiembre | 11 | 4 | 15 |
| 2020 Agosto | 15 | 3 | 18 |
| 2020 Julio | 7 | 4 | 11 |
| 2020 Junio | 8 | 9 | 17 |
| 2020 Mayo | 11 | 7 | 18 |
| 2020 Abril | 4 | 5 | 9 |
| 2020 Marzo | 8 | 13 | 21 |
| 2020 Febrero | 10 | 5 | 15 |
| 2020 Enero | 8 | 27 | 35 |
| 2019 Diciembre | 8 | 11 | 19 |
| 2019 Noviembre | 4 | 4 | 8 |
| 2019 Octubre | 4 | 5 | 9 |
| 2019 Septiembre | 10 | 7 | 17 |
| 2019 Agosto | 4 | 5 | 9 |
| 2019 Julio | 11 | 18 | 29 |
| 2019 Junio | 20 | 16 | 36 |
| 2019 Mayo | 64 | 35 | 99 |
| 2019 Abril | 15 | 39 | 54 |
| 2019 Marzo | 2 | 9 | 11 |
| 2019 Febrero | 7 | 5 | 12 |
| 2019 Enero | 1 | 9 | 10 |
| 2018 Diciembre | 4 | 7 | 11 |
| 2018 Noviembre | 1 | 15 | 16 |
| 2018 Octubre | 4 | 5 | 9 |
| 2018 Septiembre | 2 | 1 | 3 |
| 2018 Agosto | 6 | 7 | 13 |
| 2018 Julio | 5 | 4 | 9 |
| 2018 Junio | 4 | 6 | 10 |
| 2018 Mayo | 4 | 5 | 9 |
| 2018 Abril | 1 | 4 | 5 |
| 2018 Marzo | 2 | 1 | 3 |
| 2018 Febrero | 2 | 1 | 3 |
| 2018 Enero | 5 | 1 | 6 |
| 2017 Diciembre | 8 | 0 | 8 |
| 2017 Noviembre | 4 | 1 | 5 |
| 2017 Octubre | 7 | 4 | 11 |
| 2017 Septiembre | 6 | 2 | 8 |
| 2017 Agosto | 7 | 0 | 7 |
| 2017 Julio | 11 | 3 | 14 |
| 2017 Junio | 17 | 4 | 21 |
| 2017 Mayo | 16 | 0 | 16 |
| 2017 Abril | 20 | 7 | 27 |
| 2017 Marzo | 19 | 1 | 20 |
| 2017 Febrero | 13 | 4 | 17 |
| 2017 Enero | 19 | 0 | 19 |
| 2016 Diciembre | 25 | 3 | 28 |
| 2016 Noviembre | 24 | 5 | 29 |
| 2016 Octubre | 37 | 6 | 43 |
| 2016 Septiembre | 24 | 7 | 31 |
| 2016 Agosto | 19 | 2 | 21 |
| 2016 Julio | 8 | 2 | 10 |
| 2016 Junio | 9 | 9 | 18 |
| 2016 Mayo | 17 | 5 | 22 |
| 2016 Abril | 13 | 4 | 17 |
| 2016 Marzo | 15 | 8 | 23 |
| 2016 Febrero | 6 | 5 | 11 |
| 2016 Enero | 14 | 6 | 20 |
| 2015 Diciembre | 8 | 8 | 16 |
| 2015 Noviembre | 11 | 7 | 18 |
| 2015 Octubre | 17 | 5 | 22 |
| 2015 Septiembre | 12 | 2 | 14 |
| 2015 Agosto | 10 | 3 | 13 |
| 2015 Julio | 11 | 7 | 18 |
| 2015 Junio | 9 | 1 | 10 |
| 2015 Mayo | 12 | 1 | 13 |
| 2015 Abril | 11 | 6 | 17 |
| 2015 Marzo | 15 | 4 | 19 |
| 2015 Febrero | 24 | 4 | 28 |
| 2015 Enero | 22 | 4 | 26 |
| 2014 Diciembre | 13 | 6 | 19 |
| 2014 Noviembre | 11 | 1 | 12 |
| 2014 Octubre | 19 | 1 | 20 |
| 2014 Septiembre | 15 | 2 | 17 |
| 2014 Agosto | 13 | 2 | 15 |
| 2014 Julio | 27 | 2 | 29 |
| 2014 Junio | 25 | 7 | 32 |
| 2014 Mayo | 12 | 2 | 14 |
| 2014 Abril | 13 | 4 | 17 |
| 2014 Marzo | 12 | 1 | 13 |
| 2014 Febrero | 15 | 0 | 15 |
| 2014 Enero | 19 | 1 | 20 |
| 2013 Diciembre | 16 | 4 | 20 |
| 2013 Noviembre | 19 | 1 | 20 |
| 2013 Octubre | 23 | 4 | 27 |
| 2013 Septiembre | 18 | 2 | 20 |
| 2013 Agosto | 49 | 1 | 50 |
| 2013 Julio | 36 | 1 | 37 |
| 2009 Diciembre | 326 | 0 | 326 |
Mostrar todo
